Table 2.

Thioguanine dosages and adjustments during therapy

	CD [N = 66]	UC [N = 42]	Total [N = 108]
TG dosage at baseline
10 mg/day	6 [9%]	10 [24%]	16 [15%]
15 mg/day	1 [2%]	0 [0%]	1 [1%]
20 mg/day	52 [79%]	30 [71%]	82 [76%]
25 mg/day	7 [11%]	2 [5%]	9 [8%]
TG dosage at remission
10 mg/day	4 [6%]	8 [19%]	12 [11%]
15 mg/day	1 [2%]	0 [0%]	1 [1%]
20 mg/day	53 [80%]	33 [79%]	86 [80%]
25 mg/day	8 [12%]	1 [2%]	9 [8%]
Adjustments in dosages
None	53 [80%]	23 [55%]	76 [70%]
Increase	4 [6%]	3 [7%]	7 [7%]
Decrease	2 [3%]	5 [12%]	7 [7%]
Both increase and decrease	7 [11%]	11 [26%]	18 [17%]

Thioguanine [TG] treatment characteristics at baseline and during follow-up. CD: Crohn’s disease; UC: ulcerative colitis.